SEC Form 10-Q filed by Janux Therapeutics Inc.
$JANX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $69.00 | Buy | UBS |
| 9/6/2024 | $70.00 | Buy | Stifel |
| 5/30/2024 | $47.00 | Sector Perform | Scotiabank |
| 3/21/2024 | $62.00 | Buy | BTIG Research |
| 3/20/2024 | $100.00 | Overweight | Cantor Fitzgerald |
| 4/6/2023 | $24.00 | Outperform | Wedbush |
| 11/14/2022 | Outperform | William Blair |
UBS initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $69.00
Stifel initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00
Scotiabank initiated coverage of Janux Therapeutics with a rating of Sector Perform and set a new price target of $47.00
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2024 $658.0 million in cash and cash equivalents and short-term investments at end of third quarter 2024 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 Appointed Eric Dobmeier and Natasha Hernday to the Board of Directors Received $7.5 million development milestone payment from Merck $646.3 million in cash and cash equivalents and short-term investments at end of second quarter 2024 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Imm
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to
10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)
8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
144 - Janux Therapeutics, Inc. (0001817713) (Subject)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer. "The appointment of Tommy to CSO is another important milestone for our company. Tommy was essential in our initial efforts to discover and engineer a tumor-activated technology for solid tumors and has since played a critical role in optimizing the applications for our TRACTr and TRACIr platforms while supporting our clinical
Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer Management team bolstered with key appointment $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 In July, further strengthened balance sheet with approximately $60 million offering Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
The company announced the appointment of Eric Dobmeier and Natasha Hernday to its Board of Directors.
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o
U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday. Shares of UnitedHealth Group Incorporated (NYSE:UNH) rose sharply during Tuesday's session following a second-quarter earnings beat. The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from Benzinga Pro. UnitedHealth’s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare. UnitedHealth Group shares gained 5.7% to $544.96 on Tuesday. Here are some other big stocks recording gains in today’s
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)